Clearmind Partners to Develop Intranasal MEAI Formulation for Addiction & CNS Disorders
CMND is trading near its 52-week low of $1.33 (9.9% above the low) on elevated volume (12× avg).
Summary
Clearmind Medicine Inc. has entered a development agreement with Polyrizon Ltd. to create an optimized intranasal formulation for its lead compound, MEAI, targeting addiction and CNS disorders.
Key Events · Product Development and Regulatory · CMND
-
Development Agreement for MEAI Formulation
Clearmind Medicine has partnered with Polyrizon Ltd. to develop an optimized intranasal formulation for MEAI, its lead non-hallucinogenic neuroplastogen.
-
Enhanced Drug Delivery
The collaboration aims to leverage Polyrizon's hydrogel technology to improve MEAI's bioavailability, achieve faster onset of absorption, and enhance patient usability for addiction and CNS disorders.
-
Strategic Pipeline Advancement
This agreement represents a strategic step in advancing Clearmind's pipeline, potentially improving the therapeutic outcomes and market potential of its key compound.
Analysis · CMND · Life Sciences
This agreement is a strategic move for Clearmind Medicine, a clinical-stage biotech, to enhance the delivery and potential efficacy of its lead non-hallucinogenic neuroplastogen, MEAI. By leveraging Polyrizon's intranasal hydrogel technology, Clearmind aims to improve bioavailability, achieve faster absorption, and optimize patient experience for MEAI, which is being developed for addiction-related and other central nervous system conditions. This development is particularly important for a company that recently disclosed going concern doubts (January 20, 2026 filing), as it demonstrates continued progress on its core pipeline. The partnership with a related party, Polyrizon, while noted, does not overshadow the potential benefits of an improved drug delivery system for MEAI.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2797 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.33 to $59.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.